RxDoctor Payments Data

Arkady Selenow, OD

Optometrist · New York, NYNPI 1982678199

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $28,000 of the $28,169 with a category attached, or 99.4%. Johnson & Johnson Vision Care, Inc. accounts for 99.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $28,039 and has fallen 99.9% since, to $34 in 2024. Among optometrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,169in general payments, 2019–2025

Across 8 payments — averaging $3521.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$28K
  • Johnson & Johnson Surgical Vision, Inc.$39
  • Alcon$34
  • Coopervision Inc.$23
  • Oyster Point Pharma, Inc.$21
  • Bausch & Lomb Americas Inc.$20
  • plus $32 from 2 others
$167,813in research payments, 2019–2025

Across 18 payments — averaging $9322.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Johnson & Johnson Vision Care, Inc.$112K
  • Bausch Health US, LLC$56K

What the payments were for

  • Consulting fees$28,00099%
  • Food & beverage$1691%

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$28,169 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$172,540
Medicare patients
255
Services billed
2,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Brimonidine Tartrate12$353
Timolol Maleate36$308
Latanoprost51$273

Paid to pharmacies, not to this prescriber.

Other optometrist in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →